{
  "id": 17219805,
  "title": "Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game",
  "url": "https://urgent.news/2026/10/30/earnings-roundup-lillys-unwavering-momentum-novartis-rebound-and-gsks",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-30T11:50:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/biopharma-earnings-q3-2026-lilly-novartis-gsk/873167/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor angst.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}